Negative / Null Result ReportOpen accessMedicine· cited by 38

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus

Woo‐Ri Shin; Hyun Tae Lee; Heejin Lim; Sang Hyung Lee; Ji Young Son; Jee Un Lee; Ki Young Yoo; Seong Eon Ryu · 2018 · Nature Communications

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BAFF, a member of the TNF superfamily, has been recognized as a good target for autoimmune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF-belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF-receptor interaction, but also disrupting the formation of th

Abstract by Woo‐Ri Shin; Hyun Tae Lee; Heejin Lim; Sang Hyung Lee; Ji Young Son; Jee Un Lee; Ki Young Yoo; Seong Eon Ryu, Nature Communications (2018) — licensed CC BY 4.0.

Read the full paper (open access)